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Many epithelial cancers are associated with chronic inflammation. However, the features of 
inflammation that are pro-carcinogenic are not fully understood. Regulatory T cells (Tregs) 
typically restrain overt inflammatory responses and maintain intestinal immune homeostasis. 
Their immune suppressive activity can inhibit inflammation-associated cancers. Paradoxically, 
we show that Tregs promote an oncogenic immune response to a common human symbiote 
associated with inflammatory bowel disease and colorectal cancer. Colonic Tregs initiate 
interleukin (IL)-17-mediated carcinogenesis in multiple intestinal neoplasia mice colonized with 
the human symbiote enterotoxigenic Bacteroides fragilis (ETBF). Depletion of Tregs in ETBF-
colonized C57BL/6 Foxp3DTR mice enhanced colitis but diminished tumorigenesis associated 
with shifting of the mucosal cytokine profile from IL-17 to interferon (IFN)-γ; inhibition of 
ETBF-induced colon tumorigenesis was dependent on reduced IL-17 inflammation but not 
dependent on IFN-γ. Treg enhancement of IL-17 production is cell-extrinsic. IL-2 blockade 
restored Th17 responses and tumor formation in Treg-depleted animals. Our findings demonstrate 
that Tregs limit the availability of IL-2 in the local microenvironment, suppressing excessive 
Th1-associated inflammation while permitting Th17 development necessary to promote ETBF-
triggered neoplasia. Thus, we unveil a new mechanism whereby mucosal Treg responses to 
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 Humans are colonized with trillions of microbes, predominantly bacteria. Work by numerous 
investigators combined with the Human Microbiome Project (HMP), initiated in 2007, has 
provided remarkable data that has promoted our understanding of the complexity, variability and 
biology of human associations with our microbiota at diverse body sites1. Microbiota science has 
been fostered and complemented by microbial whole genome sequencing, technical sequencing 
advances, and rapidly evolving bioinformatics.  The first phase of the HMP, completed in 2012, 
focused on establishing the ‘normal’ microbiota and now has evolved to address the key scientific 
challenge of translating what we learned to understand how the microbiota contributes to disease 
pathophysiology2. With this translation, there is optimism regarding the potential for development 
of new diagnostic and therapeutic approaches. This frontier has already yielded exciting 
observations in several fields such as atherosclerosis, obesity, and colon cancer3-5. This 
introduction will describe how Bacteroides fragilis, quite unexpectedly, became appreciated as 
having the capacity to act as either symbiote or pathogen, and it will describe gaps in our 
understanding of B. fragilis disease mechanisms, including that which is addressed in this 
dissertation.   
 All B. fragilis are obligate anaerobes that inhabit and flourish along the entire length of the 
colon where they are minority members of the normal colonic microbiota. Interest in B. fragilis 
blossomed in the 1970’s with the recognition that these organisms were the leading anaerobes in 
bloodstream infection and critical contributors to intra-abdominal abscess formation6,7. Our 
subsequent understanding that B. fragilis is relatively aerotolerant (i.e., able to grow in the 
presence of nanomolar oxygen concentrations), at least in part, explains its success in mucosal 
colonization (where oxygen tension is higher), its survival following colon perforation when 
exposed to the peritoneal cavity prior to abscess formation, and its likelihood of inducing 
bacteremia8. The capsule of B. fragilis emerged as a pivotal virulence factor key to the 
organism’s success in induction of abscess formation9. Molecular characterization of the first 
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polysaccharide purified from the surface of B. fragilis, polysaccharide A (PSA), revealed that 
PSA could both cause and induce protective immunity against abscess formation in animals10,11. 
Investigations of the capsule of B. fragilis and the host immune response to this organism led to 
two transformative observations. First, B. fragilis possess the most diverse surface polysaccharide 
gene repertoire of any known bacterium with the ability to synthesize up to 8 distinct capsular 
polysaccharides (A-H) that only populate the surface of B. fragilis one at a time12. The benefit to 
the organism of its ability to ‘change its coat’ remains unknown, for a single longitudinal human 
study suggests that B. fragilis polysaccharide expression is relatively stable in colonized human 
hosts13. Second, immunologic studies support PSA-expressing B. fragilis as a symbiote with the 
remarkable capacity to modulate homeostatic mucosal immunity as well as contribute to systemic 
immune development14,15. Most intriguingly, colonization with B. fragilis displaying PSA (strain 
NCTC9343) inhibits subsequent experimental chemically-induced (e.g., DSS, TNBS) colitis, 
likely mediated, in part, by enhanced bacterial:mucosal contact16. Hence, this strain is now 
proposed as a potential probiotic therapeutic to moderate inflammation in the colon. However, 
this concept is challenged by the fact that most individuals are already colonized by B. fragilis, 
and recent murine data suggests that once colonized with a Bacteroides species, mice resist re-
colonization by a different strain of the same species17. 
 Nearly in parallel with the early B. fragilis interest, in the 1980’s, Myers and colleagues 
identified that select strains of B. fragilis accounted for a portion of diarrheal disease in lambs as 
well as other livestock including piglets, calves and foals18-21. They provided evidence that these 
strains of B. fragilis (ultimately named ETBF) induced intestinal secretion in association with 
disruption of the intestinal epithelial barrier and inflammation, in contrast to the symbiotic 
colonic associations of PSA-expressing B. fragilis. Importantly, this inflammatory experimental 
phenotype was dependent on a heat-labile factor secreted by the bacteria leading to the concept 
that a novel toxin-mediated colonic disease was induced by B. fragilis. As discussed in more 
detail below, the heat labile factor secreted by these colon disease-inducing strains of B. fragilis 
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was determined to be a metalloprotease protein toxin (most often termed B. fragilis toxin or 
BFT). Strains of B. fragilis possessing the toxin gene (bft) were termed enterotoxigenic B. fragilis 
(ETBF); whereas strains of B. fragilis lacking the bft gene were designated nonenterotoxigenic B. 
fragilis (NTBF). 
 Because enteric disease in humans is often a zoonosis, ETBF was subsequently sought as a 
cause of human diarrheal disease in a controlled study pioneered by Drs. Lyle Myers and R. 
Bradley Sack in 1992 in the pediatric outpatient clinics of the Apache Indian reservation in 
Whiteriver, AZ. This study revealed that children <1 year of age did not develop ETBF-
associated diarrhea whereas diarrhea was associated with ETBF detection in children between the 
ages of one and five years. Importantly, B. fragilis was isolated from similar proportions of 
children in each age group22. Subsequently, the largest single study conducted in adults (older 
than 15 years, N=728) in Sweden identified ETBF in 27% of adults hospitalized with acute 
community-acquired diarrhea compared to 12% of 194 healthy outpatient controls. Although 
asymptomatic fecal detection of ETBF in the control groups of diarrheal disease studies from 
around the world was sometimes common, ranging from 0-29%, well-controlled epidemiological 
studies, nonetheless, repeatedly established an association of ETBF with human diarrheal 
disease23. 
 A key clinical study conducted at the International Center for Diarrheal Disease Research 
(ICDDR,B) in Dhaka, Bangladesh changed the perspective on human ETBF disease. In this 
study, ETBF diarrheal disease was unexpectedly associated with fecal leukocytes and 
proinflammatory cytokines [interleukin (IL)-8 and tumor necrosis factor (TNF)-α], implicating 
ETBF as an etiology of inflammatory diarrhea disease24. Notably, the clinical observations of 
ETBF diarrhea at the ICDDR,B were consistent with the early observations in animals where 
colitis was observed in field and experimental infections. Consistent with the inflammatory 
potential of ETBF in the colon, limited studies to date suggest an association with active 
inflammatory bowel disease25,26. 
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 Altogether, these findings pointed towards acquisition of ETBF as a cause of acute, 
symptomatic inflammatory diarrhea and, further, that chronic asymptomatic colonization in 
humans of all ages was relatively common. However, our understanding of human ETBF 
epidemiology remains sparse. For example, we do not know whether asymptomatic colonization 
alone occurs in some hosts or stems from one of the frequent, but undiagnosed, diarrheal illnesses 
that all humans experience; whether human colonization begins most often in childhood and then 
persists; or whether some hosts can eliminate ETBF colonization through, as yet, unidentified 
immune mechanisms. 
 As mentioned previously, ETBF strains are so named because they secrete BFT, which 
remains the only known virulence factor for ETBF. Three BFT isotypes (encoded by the genes 
bft-1, bft-2, and bft-3) are known. BFT-2 exhibits greater specific activity as well as biologic 
activity in vitro and in vivo than BFT-1 with fewer details available regarding BFT-327-29. To 
date, no ETBF strain has been identified with two different bft isotype genes and most contain 
one bft copy; occasional ETBF strains possess two bft gene copies of the same bft isotype.  
 Although also referred to as fragilysin in the literature, BFT does not exhibit cell lytic activity 
but rather promotes cell proliferation. The in vitro biologic activities identified for BFT occur 
swiftly and provide potential mechanisms by which ETBF induces inflammatory diarrhea and 
intersects with mechanisms of colon carcinogenesis.  In colonic epithelial cell monolayers in 
vitro, BFT increases barrier permeability with active secretion of chloride ions, actions known to 
promote colon inflammation and carcinogenesis as well as diarrhea. BFT-induced increased 
barrier permeability correlates with cleavage of E-cadherin, an intercellular adhesion protein of 
the zonula occludens30-32. Although BFT is a protease toxin, the data do not support direct 
cleavage of E-cadherin by BFT, nor does BFT modify known protease-activated receptors 
(PARs) 33. Rather, BFT acts via a specific, yet unknown, colonic epithelial cell surface receptor 
that precipitates E-cadherin cleavage. Processing of the intracellular E-cadherin fragment by host 
cell presenilin-1/γ-secretase follows initial shedding of the E-cadherin ectodomain.  
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 Tethered to the intracellular domain of E-cadherin is β–catenin, a critical signaling molecule 
of the Wnt pathway whose actions are regulated, in part, by the adenomatous polyposis coli 
(APC) protein known to be mutated in the vast majority of human colorectal cancer (CRC) cases. 
Wnt signaling is one regulator of cell proliferation and, in the setting of mutant APC, enhanced 
β–catenin nuclear signaling results in dysregulated colonic epithelial cell proliferation. Consistent 
with this, Wu et al showed that BFT-induced degradation of E-cadherin augmented β–catenin 
nuclear signaling with induction of the oncogene c-myc, and upregulation of c-Myc expression 
contributed to BFT-induced colonic epithelial cell proliferation34. Other studies revealed 
alternative mechanisms by which BFT could be carcinogenic. Namely, BFT induces the 
polyamine catalyst, spermine oxidase (SMO) that triggers reactive oxygen species (ROS) 
production, DNA damage and cell proliferation35. 
 The range of colonic epithelial cell signal transduction activated by BFT is remarkably broad 
and incompletely understood. For example, BFT also activates nuclear factor (NF)-κB and 
mitogen-activated protein kinase signaling in colonic epithelial cells resulting in their release of 
pro-inflammatory chemokines (such as IL-8, TNF-α among others) 36,37. These chemokines are 
released across the basolateral membrane of colonic epithelial cell monolayers where they can 
foster recruitment of neutrophils and other immune cells to the colonic mucosa. BFT also induces 
colonic epithelial cell expression of cyclooxygenase (COX)-2 (but not COX-1), increasing 
mucosal prostaglandin E238. These mechanisms likely contribute to ETBF-induced inflammatory 
diarrhea in animals and humans. 
  Thus, cleavage of E-cadherin, activation of NF-κB (with anti-apoptotic effects), increased 
polyamine metabolism and induction of DNA damage within the colonic epithelium are key BFT 
oncogenic mechanisms identified to date in in vitro studies. E-cadherin cleavage yields multiple 
pro-carcinogenic outcomes that are well demonstrated in murine models of colon carcinogenesis, 
including Wnt signaling, colonic epithelial cell proliferation39 and epithelial barrier disruption 
that promotes mucosal inflammation and colon tumor formation40,41. Additionally, colonization 
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with ETBF in patients with CRC might contribute to cancer metastasis because epithelial tumors 
with reduced E-cadherin exhibit increased metastatic potential. Pro-oncogenic activities of NF-κB 
and SMO activation include induction of mucosal inflammation57-59 60, enhanced epithelial cell 
survival or proliferation, DNA damage, and/or promotion of angiogenesis42,43. 
 The clinical observation that ETBF causes human inflammatory diarrhea combined with the 
in vitro studies of BFT mechanism(s) of action led to the hypothesis that ETBF were carcinogenic 
bacteria. This hypothesis was tested in mice chronically colonized with ETBF (bft2). Notably, 
germ-free mice developed lethal colitis in 24 hrs when colonized with ETBF but not NTBF; 
whereas a single ETBF inoculation of conventional C57Bl/6 mice resulted in acute, occasionally 
bloody, inflammatory diarrhea that gradually subsided over a week in nearly all mice44. Despite 
resolution of symptoms, colonization persisted, lasting up to one year, and was resistant to 
treatment with anti-anaerobic antibiotics. Chronic ETBF colonization induces persistent, low 
level, IL-17A-dominant colon inflammation with modest hyperplasia, foci of Stat3 activation, 
reactive oxygen species production, and DNA damage45. ETBF strains with an in-frame 
chromosomal deletion of bft do not induce colitis, and conversely, transfection of NTBF with a 
plasmid bearing bft induces colitis similar to wild-type ETBF, demonstrating the central 
contribution of BFT (‘necessary and sufficient’) to ETBF disease44.  
 The carcinogenic potential of ETBF was demonstrated in multiple intestinal neoplasia (Min) 
mice. Min mice and humans with familial adenomatous polyposis (FAP) are genotypically 
similar, possessing a heterozygous nonsense mutation in the tumor suppressor gene Apc. 
However, Min mice and FAP patients exhibit phenotypically distinct disease. Whereas the 
majority of FAP patients develop many colorectal adenomatous polyps, adenoma formation is 
largely restricted to the small bowel of Min mice46. However, when colonized with ETBF, Min 
mice developed inflammatory colitis that progressed to gross distal colon tumorigenesis, 
resembling the vast majority of human CRC cases, within four weeks47. This distal colon 
localization of ETBF-induced tumors in Min mice occurs in spite of relatively uniform ETBF 
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mucosal colonization along the colonic axis. Time course studies revealed that ETBF 
colonization of Min mice rapidly initiated tumorigenesis, with excess histologic microadenomas 
identified within 1-2 weeks after ETBF colonization, and lethal tumor burdens resulting in animal 
death within ~3 months. In contrast, histologic microadenomas are rare in sham or NTBF-
colonized mice at early time points, and they survive at least 5 months.  
 Mechanistically, ETBF induces widespread, immediate (within 2 days) then prolonged, 
activation of signal transducer and activator of transcription-3 (Stat3) in colonic epithelial cells 
and associated infiltrating immune cells. In the microenvironment of ETBF colon tumors, Stat3 
activation is accentuated compared to parental Min mouse colon tumors where more modest Stat3 
activation is detected. Predictably, since activation of the Stat3 transcription factor is integral to 
adaptive CD4+ T helper type 17 (Th17) cell differentiation, IL-17A-secreting Th17 cells dominate 
the early ETBF-associated mucosal inflammatory immune response. IL-17 blockade as well as 
depletion of CD4 cells inhibits ETBF colon tumorigenesis confirming that ETBF triggers Th17-
dependent carcinogenesis47. IL-17 is a potent chemoattractant for neutrophils, and neutrophils are 
prominent in ETBF colitis, likely releasing mutagenic ROS48. ETBF also induces SMO 
expression in vivo, and treatment of Min mice with an SMO inhibitor reduced ETBF-induced 
colonic inflammation, epithelial cell proliferation and colon tumorigenesis35.  
 Thus, these ETBF murine models confirmed the in vitro activities of BFT to induce NF-κB, 
SMO and Wnt signaling, ROS production and DNA damage. Most importantly, the oncogenic 
potential of ETBF was confirmed, and for the first time, adaptive immune responses, specifically 
Th17 adaptive immunity, were identified as carcinogenic. Since these observations, Th17 
immunity has been identified to contribute to carcinogenesis in numerous models and in human 
disease. Activation of the Stat3/IL-17 pathway, in fact, correlates with a poorer prognosis in 
human CRC49.  
In an attempt to further characterize the regulation of pro-carcinogenic IL-17 responses 
induced by ETBF colonization, we studied the role of Foxp3+ regulatory T cells (Tregs). FOXP3 
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is a critical nuclear transcription factor that imparts immunosuppressive functions to most Tregs. 
In fact, defects in Foxp3 result in the development of immunodysregulation, polyendocrinopathy, 
enteropathy, X-linked (IPEX) syndrome, or devastating autoimmune diseases50. Tregs play a 
necessary immunosuppressive role that protects against immune-mediated pathologies. Therefore, 
we expected that Tregs would diminish the magnitude of pro-carcinogenic ETBF-induced IL-17 
responses and thus mitigate tumor formation. This notion is supported by data indicating that 
depletion of Tregs ultimately leads to the development of colitis in mice not challenged with any 
colitogenic microbes, and adoptive transfer of Tregs with naïve effector (Foxp3-) CD4+ T cells 
prevents the development of experimental colitis in conventional mice51-53. Furthermore, Treg 
specific deletion of Stat3 results in the ultimate development of spontaneous Th17 colitis52.  
We found that ETBF colonization was characterized by the accumulation of activated 
Treg cells, as well as IL-17+ T cells, at the dominant site of ETBF tumorigenesis, the distal colon. 
Surprisingly, we observed that depletion of Tregs in ETBF-colonized Min mice led to the 
abrogation of tumorigenesis at the earliest stages. Colons of Treg-depleted ETBF-colonized 
animals were highly inflamed, demonstrating that the suppressive capacity of colonic Tregs 
remained intact. Notably, the inflammation in Treg-depleted ETBF-colonized animals that 
exhibited increased colitis, but decreased tumorigenesis, was characterized by elevated IFN-γ and 
profoundly decreased IL-17A in the lamina propria, resulting in loss of the characteristic Th17 
colitis normally associated with ETBF colonization. We show that Tregs promote acute IL-17-
driven colitis via local consumption of IL-2, which inhibits Th17 polarization while enhancing 
expansion of Th1 cells. While mucosal Tregs initially promote Th17 polarization, they do not 
participate in the stabilization of the IL-17 response at later stages of ETBF colitis. Thus, we 
identify an unexpected role for Tregs in promoting the early stages of immune carcinogenesis.   
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Materials and Methods 
Mice and reagents  
C57BL/6 Foxp3DTR-GFP mice were provided by A. Rudensky (Memorial Sloan-Kettering Cancer 
Center, New York, New York). C57BL/6 Rag1-/-, CD45.1, and IFN-γ-/- mice were purchased from 
Jackson Laboratories (Bar Harbor, ME). ApcΔ716 (Min) mice were obtained from Drs. David Huso 
and Bert Vogelstein. IFN-γ-/- x Foxp3DTR-GFP mice were obtained in our facility by crossing 
C57BL/6 Foxp3DTR-GFP mice with IFN-γ-/- mice. Min x Foxp3DTR-GFP mice were obtained in our 
facility by crossing C57BL/6 Foxp3DTR-GFP mice with Min mice.  In some experiments, bone 
marrow (BM) chimera mice were established by retro-orbital injection of 107 BM cells from 
donor mice into sub-lethally irradiated (300 rad) recipient C57BL/6 Rag1-/- mice. Irradiated mice 
were rested 6 hours before BM cell injection. Reconstituted mice were maintained on 
prophylactic antibiotic treatment (Sulfatrim) prior to ETBF inoculation (see below). In 
accordance with the Association for the Assessment and Accreditation of Laboratory Animal 
Care International, mice were maintained under specific pathogen-free conditions and studied 
according to protocols approved by the Johns Hopkins University Animal Care and Use 
Committee.  
 
Aqua cell viability dye was purchased from Life Technologies (Grand Island, NY). Flow 
cytometry antibodies against CD3, CD4, CD45.2, Foxp3, IL-17A, and IFN-γ were purchased 
from Affymetrix/eBioscience (San Diego, CA). Intracellular staining (ICS) was performed with 
eBioscience Foxp3 staining kit according to the manufacturer’s instructions. Anti-IL-2 mAb 
(clone S4B6) and isotype control (rat IgG2a) were purified from hybridomas purchased at 
American Type Culture Collection (Manassas, VA). 
 
ETBF mouse models 
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ETBF strain 86-5443-2-2 was used in this study 44,47. B. fragilis strains were grown anaerobically 
on BHI medium plates containing 37 g of brain heart infusion base (Difco Laboratories, Detroit, 
MI) per liter along with 5 g of yeast extract (Difco) per liter, 0.1 mg of vitamin K per liter, 0.5 mg 
of hemin per liter, 50 mg of L-cysteine, and 6 μg of clindamycin per liter (all from Sigma, St. 
Louis, MO). A single colony was inoculated into BHI broth and grown anaerobically overnight at 
37°C. Pelleted, washed bacteria were resuspended in 0.1 N sodium bicarbonate buffer and 
adjusted to an optical density corresponding to ~109 colony forming units (CFU)/ml for mouse 
inoculations. Three to 4 week old mice were treated with clindamycin and streptomycin (0.1 g/L 
and 5 g/L, respectively, in water bottles) 5 days prior to ETBF inoculation by gavage (~108 
bacteria in PBS). BM chimera mice were inoculated with ETBF 6 weeks after sub-lethal 
irradiation. All strains are resistant to these antibiotic treatments. Mice were sacrificed 7 days 
after colonization, unless otherwise noted. 
 
Treg depletion and IL-2 neutralization  
Mice received 50 ng intraperitoneal (ip) injections of diphtheria toxin (DT; Sigma-Aldrich, MO) 
per g body weight on days one and two prior to ETBF inoculation (D-2, D-1) and on days 1, 3 
and 5 after ETBF inoculation (D+1, D+3, D+5). Colons were harvested from mice 7 days after 
ETBF inoculation. In some experiments, IL-2 was neutralized by ip injection of 0.5 mg/mouse of 
anti-IL-2 mAb (clone S4B6) or isotype control (rat IgG2a) 2 days prior and every day after ETBF 
inoculation until mouse sacrifice. For tumor experiments, mice received 50 ng DT per g body 
weight on D-1, D0, D+1, D+3, and every other day until sacrifice and harvest on D+13. 
 
Lamina propria lymphocytes (LPL) isolation 
Dissected colons were flushed with 20 ml Ca2+, Mg2+ free PBS 1X and cut longitudinally. Tissues 
were cut in <0.5 mm pieces and washed 3 times for 20 min in 37oC 2mM EDTA, 10% FCS, 
25mM Hepes, HBSS buffer. Tissue pieces were subsequently digested 30 min in 5% FCS RPMI 
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in presence of 400 Unit/ml Liberase (Roche Diagnostic, Indianapolis, IN) and 0.2 mg/ml DNAse 
1 (Roche Diagnostic). Mononuclear cells were isolated by 20/40/80 Percoll gradient separation 
(GE Healthcare Life Science, Pittsburgh, PA).  
 
Flow cytometry and fluorescence-associated cell sorting (FACS) 
Colons from 1-2 mice per group were processed to obtain lamina propria lymphocytes (LPLs) as 
previously described 54. Mononuclear cells collected by Percoll gradient separation were cultured 
4hr in Iscove’s Modified Dulbecco’s Medium (IMDM) with 5% FCS and in the presence of Cell 
Stimulation Cocktail (plus protein transport inhibitors) (eBioscience). Cells were then washed and 
stained for cell surface markers followed by fixation and permeabilization (Foxp3 Fixation 
buffer, eBioscience). ICS was performed for IFN-γ, IL-17A and Foxp3. Flow cytometry 
acquisition was performed on LSRII cytometer (BD Bioscience) and data was analyzed using 




Total RNA was isolated from sorted cells or whole tissue using TRIzol® reagent from Life 
Technologies (Grand Island, NY) according to manufacturer’s instructions. 1μg of RNA was 
reverse transcribed using High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems®). 40 cycles 
of TaqMan® Gene Expression qRT-PCR was performed on 1 ng RNA per sample for indicated 
genes. ^Ct was calculated by subtracting Ct of Gapdh from Ct of target gene and averaging 2 
technical replicates.  
 
Histology and microadenoma counts 
Colons were dissected and preserved in 10% buffered formalin. Histologic examination was 
performed after hematoxylin and eosin (H&E) staining of 5 µm sections. To facilitate 
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longitudinal examination of the full-length colon, colons were ‘Swiss-rolled’ prior to embedding 
and sectioning. Total colon inflammation was scored as previously described44. Microadenoma 
counts on formalin-fixed paraffin-embedded H&E colon tissue sections from 2-week ETBF-
colonized Min mice, and all histopathology scoring, were performed by a pathologist (DH). 
 
 Statistical analysis 
Comparison of means was done by unpaired, two-tailed Mann-Whitney U testing, unless 





 Synchronized accumulation of activated mucosal Tregs and IL-17-producing cells precedes 
colon tumorigenesis in ETBF-colonized mice 
ETBF colonization of four to five week old C57Bl/6 mice (Apc+/+) elicits acute, self-limited (~3-4 
days) inflammatory diarrhea, associated with a robust mucosal IL-17 response. ETBF 
colonization then persists, leading to a chronic (≥1 year), asymptomatic Th17-mediated 
colitis44,45that promotes distal colon tumorigenesis in Min mice47 (Figure 1). Since IL-17A is 
required for ETBF-triggered tumorigenesis, we sought to understand the regulation of 
inflammation and colon tumorigenesis in the context of ETBF colonization. Because mucosal 
Tregs are instrumental in tuning the intestinal Th17 response to counter microbial aggression55 or, 
conversely, to limit excessive responses to microbial components51,56, we looked for a possible 
Treg response to ETBF. We found that early after ETBF colonization (day 7) IL-17+ and Foxp3+ 
T cell density (cells per gram of tissue) and percent of lymphocytes concurrently increased in the 
tumor-prone distal colon compared to sham (uninfected) mice (Figure 2 and 3). While there was 
little difference in the density and percentage of IL-17+ T cells between the proximal and distal 
colon of ETBF-colonized mice, the density, but not percentage, of Tregs that accumulated in the 
distal colon was significantly greater than that in the proximal colon of ETBF-colonized mice 
(Figure 2 and 3). This suggests that the density of total CD4+ T cells may be increased in the 
distal colon of ETBF-colonized mice, which is indeed the case (Figure 4). In addition, the 
proportion of CD4+ and Foxp3+ T cells with an activated phenotype, characterized by increased 
expression of CD44 and CD69 (Figure 5A), was dramatically increased in the distal, but not the 
proximal, colon after 7 days colonization with ETBF compared to sham. Tregs in ETBF-
colonized mice also expressed KLRG1 (Figure 5B), which putatively indicates increased 
suppressive function, at least in vitro57. This was interesting because the ligand for KLRG1 is E-
cadherin; however, in vivo experiments to address the functional role of KLRG1+ Tregs, with or 
without ETBF, were unsuccessful with variable results (data not shown). Nonetheless, the 
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synchronized expansion of activated and IL-17-producing T cells as well as activated Treg cells 
following ETBF colonization suggests that Treg responses may play a role in modulating IL-17-




Tregs promote colonic neoplasia in ETBF-colonized Min mice  
We previously showed that ETBF-induced colon tumorigenesis is IL-17-dependent since 
injection of an anti-IL17 blocking antibody inhibited tumor formation47. Foxp3+ Treg function in 
intestinal mucosa is typically thought to suppress excessive effector immune responses to 
microbiota and protect the integrity of the intestinal barrier58-60. Thus, we initially hypothesized 
that Tregs are necessary to limit ETBF-induced IL-17-mediated tumorigenesis. To assess the 
impact of Tregs on ETBF tumorigenesis, we crossed Min mice to Foxp3DTR-GFP mice that express 
the diphtheria toxin receptor (DTR) on Foxp3+ cells61. Intraperitoneal administration of DT, 
therefore, selectively depletes Foxp3+ cells. Because autoimmunity develops when Tregs are 
systemically depleted for more than two weeks61, we tested the impact of Treg depletion on early 
microadenoma induction by ETBF in Min mice, which develop microadenomas in the distal 
colon beginning one week after ETBF colonization. This early time window (day 13) allowed us 
to assess the effect of Foxp3+ cells on early ETBF tumorigenesis prior to any systemic effects of 
Treg depletion. DT or PBS was administered to Min x Foxp3DTR mice starting one day prior to 
ETBF inoculation and every other day thereafter until harvest at day 13. Not surprisingly, Treg-
depletion significantly increased colonic inflammation (Figure 6A and 6B), emphasizing that the 
immunosuppressive function of colonic Tregs remains intact. Surprisingly, however, 
microadenoma formation was significantly reduced in Treg-depleted mice compared to Treg 
sufficient controls (Figure 6A and 6B).  
During the acute colitis stage at one week, inflammation upon Treg depletion was similar 
to that of Treg-competent mice in sham (0.0 +/- 0.0, mean +/- SD in sham and sham + DT mice, 
p>0.999, N=7-8 mice per group) or ETBF-colonized mice (1.78 +/- 0.67 vs 2.1 +/- 0.88, ETBF vs 
ETBF + DT mice, p=0.5, N=9-10 mice per group)(Figure 7A and 7B). Of note, one week ETBF-
colonized mice with or without Treg depletion displayed marked colitis compared to sham mice 
(p<0.0001 for both comparisons, Figure 7A and 7B).  
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Tregs provide help for Th17 responses to ETBF colonization via a cell-extrinsic mechanism  
Since IL-17 induction is an absolute requirement for ETBF-induced colon tumorigenesis 47 and 
microadenoma formation was significantly reduced in ETBF-colonized Treg-depleted mice, we 
asked whether Tregs in ETBF-colonized mice modified the mucosal Th1/Th17 balance in favor 
of protumoral Th17 effectors, potentially contributing to the development of distal colon 
tumorigenesis. To determine the impact of Tregs on the Th1/Th17 balance in ETBF-colonized 
mice, lamina propria lymphocytes (LPLs) were isolated after one week from the colons of sham 
or ETBF-colonized Foxp3DTR-GFP mice treated or not with DT and analyzed for cytokine 
production by intracellular staining (ICS). Indeed, in accordance with the unexpected finding that 
Treg depletion diminished early in situ tumor formation, depletion of Tregs in ETBF-induced 
colitis dramatically reduced the proportion of Th17 cells (5 +/- 2%, N=5) in the colonic lamina 
propria compared to ETBF-colonized Treg-sufficient mice (27 +/- 8%, N=5, P < 0.0001 Figure 
8A and 8B). Notably, the effect of Treg depletion was not limited to Th17 cells as IL-17 
production by other cell types (CD4-) was also mitigated (Figure 9). Conversely, Foxp3+ Treg 
depletion in ETBF-colonized mice strongly enhanced the Th1 response with a marked increase in 
the proportion of IFN-γ+ CD4+ T cells. Since IFN-γ+ CD4+ T cells also increased in sham mice 
after Treg depletion, our data further support the concept that mucosal regulation of Th1 by Tregs 
is key to intestinal immune homeostasis (Figure 8A). 
Since STAT1/IFN-γ signaling is well established as an inhibitor of the STAT3/Th17 
pathway 62, we explored the possibility that loss of IL-17 production upon Treg depletion was 
indirectly due to inhibition by the increased Th1 response. We crossed Foxp3DTR mice to IFN-γ-/- 
mice and demonstrated that, even though T cell-generated IL-17 did trend slightly higher in IFN-
γ-/- mice compared to IFN-γ+/+ mice after Treg depletion, in the absence of IFN-γ, Treg depletion 
still mitigated the proportion of Th17 cells in LPLs (Figure 8B and 10). This result demonstrated 
that decreased IL-17 production in Treg-depleted mice is mostly not due to increases in IFN-γ. 
Because Treg cells are viewed as components of the tumor microenvironment (TME) that 
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suppress anti-tumor immunity and promote tumor growth 63, it is possible that Treg depletion 
impaired ETBF tumorigenesis by unleashing a robust anti-tumoral IFN-γ response. Thus, we 
asked whether increased IFN-γ driven inflammation in the absence of Tregs might promote 
potent anti-tumor immunity. Depletion of Tregs in Min x Foxp3DTR x IFN-γ-/- mice reduced 
microadenoma numbers similar to those observed in Treg-depleted Min x Foxp3DTR mice, 
establishing that decreased Treg-mediated IL-17 production, and not increased IFN-γ, is most 
likely responsible for reduced neoplasia (Figure 11).  
While these results suggest that Tregs are providing cell-extrinsic “help” for the 
differentiation of naïve CD4+ LPL to Th17, it is possible that the effects of Foxp3+ cell depletion 
could be cell-intrinsic, i.e. via depletion of Foxp3+ precursors to the colonic Th17 cells. Indeed, 
there is evidence that Th17 cells and peripherally induced Tregs may differentiate from a 
common Foxp3+RORγt+ precursor, or Th17 cells may result from “trans-differentiation” of Tregs 
64,65. Consistent with a potential intrinsic mechanism of Foxp3 in cells differentiating into Th17 
cells, we indeed observed the presence of IL-17+ Foxp3+ CD4+ T cells in colon tumors (Figure 
12).  
To distinguish whether Foxp3 marked precursors to Th17 cells (intrinsic mechanism) or 
if Foxp3+ Treg help was necessary for Th17 differentiation (extrinsic mechanism) in ETBF 
colitis, we transferred both CD45.2+ Foxp3DTR and CD45.1+ Foxp3WT bone marrow (BM) at a 1:1 
ratio into sub-lethally irradiated RAG1-/- recipients, establishing mixed BM chimera mice. This 
approach allowed us to selectively deplete CD45.2+ Foxp3DTR Tregs following DT injection, and 
it enabled us to monitor the origin (CD45.1+ or CD45.2+ BM) of the Th17 cells during ETBF 
colitis (Figure 13A). Upon CD45.2+ Foxp3+ depletion, a cell intrinsic mechanism would only 
diminish Th17 responses among CD45.2+ T cells while a cell extrinsic mechanism would not 
diminish Th17 responses among either CD45.1+ or CD45.2+ T cells. When CD45.2+ Foxp3DTR 
cells were depleted in the mixed BM chimeras, we found that neither CD45.1+ (i.e. CD45.2-) nor 
CD45.2+ Th17 cells were decreased compared to Treg sufficient mixed BM chimeras (Figure 
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13B). In these experiments, CD45.2+ Tregs were fully depleted, but CD45.1+ Tregs were 
unaffected (Figure 13B). As a positive control for the action of DT, we depleted total Tregs from 
ETBF-colonized CD45.2+ Foxp3DTR BM chimeras. As expected, this resulted in a Th17 
proportion in LPLs similar to the sham mixed BM chimera mice (Figure 13B). In order to 
determine at which point Tregs enhanced ETBF-induced Th17 responses, DT was administered 
one day post ETBF inoculation (late depletion), in contrast to the experiments described above in 
which DT was given two days prior to ETBF inoculation. In striking contrast to Treg depletion 
prior to ETBF colonization, late depletion of Tregs resulted in a Th17 response that was 
comparable to that of Treg sufficient ETBF-colonized mice (Figure 14). Taken together, these 
results suggest that Foxp3+ Tregs provided extrinsic support for initial Th17 differentiation, but 
not maintenance, in response to ETBF. Regardless of when Treg depletion was initiated (early 




Tregs promote Th17 development in the colon via consumption of IL-2 
Tregs, which express high levels of IL-2 receptors, particularly when activated, do not produce 
endogenous IL-2. Thus, they are extremely dependent on exogenous sources of IL-2 for their 
survival. Treg proliferation and activation upon ETBF colonization may therefore deprive the 
local inflammatory environment of IL-2. Since IL-2 down-regulates IL-17 production via STAT5 
signaling, Tregs may promote Th17 differentiation by limiting the amount of local IL-2 available 
to uncommitted T cells 66-68. In contrast, IL-2 may promote proliferation of Th1 cells 69. To 
determine whether Treg promotion of Th17 differentiation upon ETBF colonization occurs via 
limiting local IL-2, ETBF-colonized Treg-depleted Foxp3DTR mice were injected with a blocking 
antibody against IL-2 (S4B6-1) and LPLs were isolated after 7 days of ETBF colonization. 
Figure 15 shows that anti-IL-2 treatment indeed restored the Th17 response to ETBF in the 
absence of Treg cells. In contrast, when Treg cells were present, anti-IL-2 treatment minimally 
increased the proportion of Th17 cells (Figure 15A and 15B). In keeping with the notion that IL-
2 expands Th1 cells, anti-IL-2 treatment partially mitigated the increase in IFN-γ-producing cells 
upon Treg depletion (Figure 15A). When Tregs were depleted, the expression of total IL-17 
mRNA was similarly restored when anti-IL-2 mAb was administered (Figure 16). The decreased 
availability of IL-2 likely resulted from cytokine consumption by Tregs (“sink effect”) and not 
inhibition of IL-2 production by effector cells as IL-2 mRNA expression was indeed similar 
between effector T cells (CD11b- Foxp3- CD4+ or CD8+) sorted from LPLs of ETBF-colonized 
Treg-sufficient and Treg-deficient mice (Figure 17). As expected, expression of Foxp3 was low 
in both groups of effector T cells, and IL-17 mRNA was decreased in effector T cells sorted from 
Treg-depleted mice compared to effector T cells from Treg-sufficient mice (Figure 17). 
Importantly, when IL-17 is increased in Treg-depleted Min x Foxp3DTR mice treated with anti-
mouse IL-2 mAb, microadenoma formation was restored (Figure 18A), demonstrating that the 
IL-17-dependent protumoral activity of mucosal Tregs in the ETBF-driven TME requires IL-2 
deprivation. Despite the restoration of microadenomas upon anti-IL-2 treatment of Foxp3-
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depleted mice, colonic inflammation was reduced compared to Treg-depleted isotype-treated Min 
x Foxp3DTR mice (Figure 18B). The enhanced colitis of Treg depletion was also reduced in Treg-
depleted IFN-γ-/- mice (Figure 18B). These results dissociate colitis from tumorigenesis in that 
Th1-mediated colitis upon Treg depletion (Figure 8A) does not induce microadenomas as Th17-
mediated colitis does (Figure 6B). Thus, we conclude that Treg cells facilitate Th17 
differentiation in the inflammatory microenvironment of the ETBF-colonized colon by limiting 






In an effort to further understand the mechanisms of ETBF-driven procarcinogenic colitis, we 
investigated the impact of mucosal Treg cells on the inflammatory response to ETBF murine 
colonization. These studies led to the surprising conclusion that Tregs are critical to initiate the 
Th17 colitis necessary for tumor induction. Through consumption of IL-2, Tregs inhibit the 
development of Th1 colitis, which is not procarcinogenic, and shift T cell differentiation to Th17 
in the lamina propria of ETBF-colonized mice. This helper role of Tregs for Th17 development 
occurs only at the very initial stages of ETBF-mediated colitis.  
Recent reports showed that mucosal Tregs, which commonly orchestrate mucosal 
immune homeostasis by restraining inflammatory responses to microbiota in the gut, can 
cooperate with immune effector cells to protect against and eradicate infections55,67. Th17 cells, 
by their production of IL-17, are predicted to be important to the mucosal defense against ETBF, 
resulting in the recruitment of bactericidal polymorphonuclear and phagocytic mononuclear cells. 
Consistent with this idea, IL-17-/- mice colonized with ETBF exhibit increased morbidity and 
mortality compared to wild-type mice (C Dejea, C Sears, unpublished). However, the mucosal 
Th17 defenses against ETBF are not antiseptic and thus do not prevent chronic colitis associated 
with the persistence of both ETBF and mucosal IL-17 production45. In conjunction with a host 
genetic predisposition, such as the Apc mutation in Min mice, ETBF-induced mucosal IL-17 is 
instrumental in promoting marked distal colon tumorigenesis47. Importantly, a predominant IL-17 
response is associated with worse survival in human CRC49. ETBF represents the first common 
human commensal identified as a potent trigger for murine colon tumorigenesis47,70. Surprisingly, 
ETBF triggers its carcinogenic IL-17 response, in part, through the accumulation of mucosal 
Tregs. This is in stark contrast to the mucosal immune homeostasis proposed as resulting from 
nontoxigenic B. fragilis-mediated Treg induction14,16. Our results show that ETBF-mediated 
colitis drives the accumulation of Foxp3+ Tregs that, despite their suppression of Th1 mucosal 
inflammation, consume IL-2 resulting in Th17 polarization that is critical to ETBF tumorigenesis. 
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IL-2 is a potent inhibitor of IL-17 production via competition between STAT5 (IL-2 signaling) 
and STAT3 (IL-17 signaling) for binding to the Il17 promoter 71. Further, Tregs are incapable of 
producing IL-2 and are highly dependent on exogenous sources of IL-2, indispensable to their 
survival72,73. Thus, Tregs capture IL-2 in their environment via their elevated constitutive 
expression of the high affinity IL-2 receptor, CD25. By modulating levels of exogenous IL-2, 
Tregs release the STAT5 inhibitory effect on Th17 differentiation of uncommitted CD4+ T cells 
or suppress already-committed effector T cells by IL-2 deprivation73,74. Although Tregs have also 
been shown to inhibit IL-2 production by effector T cells (endogenous IL-2) 73,75, we have shown 
herein that ETBF-induced Tregs do not alter IL-2 transcription by lamina propria effector T cells. 
Importantly, our results establish that Tregs strictly intervened at the initiation stage of Th17 
differentiation, but they are not required for the stabilization of the colonic Th17 immune 
signature since late Treg depletion does not impair the Th17 response to ETBF infection (Figure 
14). Our findings described here may be related to those of Pandiyan et al. who showed in a 
murine model of oral Candida albicans that poorly suppressive Tregs were important to initiate 
the anti-fungal Th17 response, but they eventually resumed their suppressive function and 
inhibited pathogenic Th17 effectors 67.  
Because Treg and Th17 cells demonstrate functional plasticity, we experimentally ruled 
out the possibility that ablation of Foxp3 limited Th17 cells generated via elimination of Foxp3+ 
progenitors. Tregs have been reported to convert into IL-17 or IFN-γ-producing cells 76-78, and 
Th17 cells have been reported to up-regulate Tbet and produce IFN-γ79,80 or up-regulate Foxp3 
and acquire suppressive function65,81. Xu et al demonstrated that, in the presence of IL-6, Foxp3+ 
Tregs can be induced to become Th17 cells. Moreover, IL-17+RORγt+ Tregs have been detected 
in mouse and human cancer and have been shown to be highly pathogenic82. Even though a small 
proportion of IL-17+Foxp3+ T cells was detected in the colons of ETBF-colonized mice (Figure 
12), our use of mixed BM chimeras demonstrated that ablation of CD45.2+ BM derived Foxp3+ 
Tregs did not impair the generation of CD45.2+ Th17 cells when CD45.1+ Tregs were present. 
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This indicated Tregs act to promote Th17 differentiation via an extrinsic mechanism in the ETBF 
murine model.  
Our study showed that, in the absence of Tregs, ETBF colonization induced a strong 
inflammatory response associated with increased IFN-γ production. Although commonly 
associated with anti-tumor host defenses, we demonstrated that the IFN-γ/Th1-type immune 
response was not responsible for reduced colon neoplasia in Treg depleted-ETBF-colonized Min 
mice. This result highlights the impact of IL-17 in tumor initiation. The increased IFN-γ response 
to Treg depletion is not surprising, especially in the gut where there is constant exposure to 
inflammatory stimuli such as pathogen-associated molecular patterns on commensal bacteria. In 
fact, Treg cell depletion has recently been shown to increase the inflammatory cytokines IFN-γ 
and IL-17 in the intestines 51, and adoptive transfer of Treg cells can cure experimental models of 
inflammatory bowel disease53,83. These data emphasize that Tregs exercise strong 
immunosuppressive function on effector T cells in other settings. However, in ETBF 
colonization, mucosal Tregs polarize a robust IL-17 mucosal immunity while suppressing Th1 
immunity. We noted that the inflammation score one week following ETBF colonization, in 
contrast to inflammation following 13 days of ETBF colonization, remained similar with or 
without Tregs; however, the character of this inflammation differed, with Tregs promoting IL-17 
while repressing IFN-γ. 
Our findings allow a better understanding of the Th17 polarization induced by ETBF 
colonization and its contribution to colon tumorigenesis. However, the cellular and molecular 
mechanisms by which ETBF selectively increases Tregs in the distal murine colon remain 
unknown. As BFT, which profoundly alters the biology of colonic epithelial cells84, is required 
for ETBF-driven oncogenic IL-17 production, we postulate that epithelial-derived signals, 
following the rapid cleavage of E-cadherin induced by BFT32, contribute to the recruitment of 
effector immune cells, including Tregs. It has recently been shown that diminished epithelial 
barrier function induced the production of alarmins that directly recruit and activate Tregs85. For 
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example, IL-33 stimulated Tregs and opposed the restraining effect of proinflammatory IL-23 on 
Tregs in microbiota-induced chronic colitis. Additional inflammatory signals, including those 
potentially provided by BFT-altered epithelial cells, may play a critical role in the Treg response 
to ETBF and promotion of protumoral IL-17 production. Furthermore, while the precise 
mechanism by which IL-17 contributes to ETBF-mediated tumorigenesis is still unclear, IL-17 
has been shown to directly influence colon epithelial cell signaling, survival, and proliferation 86. 
The elucidation of IL-17-induced epithelial-derived signaling pathways will contribute to a better 
understanding of the regional distribution of ETBF-induced colon tumors and may eventually 
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Figure 1: ETBF-induced distal colon tumorigenesis. Methylene blue-stained colon of 2 month 
ETBF-colonized Min mouse. The distal colon predominance of ETBF tumorigenesis is shown 











Figure 2: Accumulation of IL-17+ T cells in proximal and distal colons of ETBF-colonized 
mice. Lamina propria lymphocytes (LPLs) were isolated from proximal and distal colons (as 
demarcated in Figure 1) of C57Bl/6 mice 7 days after sham (PBS) or ETBF inoculation and 4 hr 
culture with Cell Stimulation Cocktail preceded intracellular staining (ICS) for IL-17A. Live 
CD3+ IL-17+ cell numbers were normalized by the mass of colon tissue after cleaning and before 
LPL isolation (top). Percent IL-17+ of live CD3+ lymphocytes (bottom). Each symbol represents 
one sample, and error bars represent one standard deviation from the mean in each direction. 









Figure 3: Accumulation of Foxp3+ Tregs in proximal and distal colons of ETBF-colonized 
mice. LPLs were isolated from proximal and distal colons of C57Bl/6 mice 7 days after sham 
(PBS) or ETBF inoculation. ICS for Foxp3 on proximal and distal colon LPLs from C57Bl/6 
mice was performed fresh ex vivo without stimulation. Live CD3+ CD4+ Foxp3+ cell numbers 
normalized by mass of colon tissue as in Figure 2 (top). Percent Foxp3+ of live CD3+ CD4+ 
lymphocytes (bottom). Each symbol represents one sample, and error bars represent one standard 
deviation from the mean in each direction. Shown are data from two separate experiments. Pc = 








Figure 4: Accumulation of total CD4+ T cells in distal colons of ETBF-colonized mice. Live 
CD3+ CD4+ LPL numbers from Figure 3 normalized by mass of colon tissue. Each symbol 
represents one sample, and error bars represent one standard deviation from the mean in each 







Figure 5: Activated phenotype of CD4+ T cells and Tregs in colons of ETBF-colonized mice. 
LPLs were isolated from proximal and distal colons of C57Bl/6 mice 7 days after sham (PBS) or 
ETBF inoculation. Surface staining and ICS for Foxp3 on proximal and distal colon LPLs from 
C57Bl/6 mice was performed fresh ex vivo without stimulation. A) Percentages are of live CD3+ 
CD4+ lymphocytes (top) and of live CD3+ CD4+ Foxp3+ lymphocytes (bottom) in the indicated 
quadrant. B) Histogram of live CD4+ Foxp3+ cells; percentages of KLRG1+ Tregs from distal 
colon of ETBF-colonized mice (58.3%) and sham mice (27.3%). Results shown are 






Figure 6: Treg depletion enhances inflammation but reduces microadenoma formation in 
Min mice. B6.Foxp3DTRxMin mice were inoculated with ETBF on day 0. Either 150 μl purified 
sterile H2O or 50 ng/g diphtheria toxin (DT) was administered intraperitoneal (ip) on days -1, 0, 
1, 3, and every other day until sacrifice and harvest. Colons were harvested on day 13, cleaned, 
rolled, and fixed in 10% formalin for histology & scoring. A) Images are of distal colon. 
Microadenoma is encircled. Scale bars are 50 μm. B) Each symbol represents total inflammation 
score (left) or microadenomas counted (right) per Min mouse colon from Figure 6A. Data shown 





Figure 7: ETBF colonization induces acute colitis at 1 week that is unaffected by Treg 
depletion. B6.Foxp3DTR mice were inoculated with sham or ETBF on day 0. Either 150 μl 
purified sterile H2O or 50 ng/g diphtheria toxin (DT) was administered intraperitoneal (ip) on 
days -2, -1, 0, 1, 3, and 5 until sacrifice and harvest. Colons were harvested on day 7, cleaned, 
rolled, fixed in 10% formalin, paraffin embedded, and H&E stained for histology & scoring. A) 
Images are of distal colon. Scale bars are 50 μm. B) Each symbol represents total inflammation 
score per mouse colon from Figure 7A. Data shown include 2 separate experiments with 2-6 








Figure 8: Treg depletion mitigates the Th17 response to ETBF in favor of a Th1 response. 
Colon LPLs from 1-2 B6.Foxp3DTR mice per group were harvested on day 7 following 
inoculation with ETBF or Sham on day 0. Either 150 μl purified sterile H2O or 50ng/g DT was 
administered ip on days -2, -1, 1, 3, & 5. Cells were stimulated ex vivo, followed by ICS. A) 
Plots show viable CD3+ CD4+ Foxp3- LPLs and are a representation of 4-5 separate 
experiments. B) Aggregate data from combined experiments showing percentage of viable CD3+ 
CD4+ Foxp3- LPLs that are IL-17A+. Each symbol represents 1-2 Treg-depleted B6.Foxp3DTR 
mice (, +DT) or Treg-sufficient mice (, No DT), and error bars represent 1 standard deviation 
from the mean in each direction. Holm-Sidak method for multiple comparisons was used to 









Figure 9: Mitigation of IL-17 response to ETBF in the absence of Tregs is not restricted to 
CD4+ (Th17) cells. B6.Foxp3DTR mice were inoculated with ETBF. Either 150 μl purified 
sterile H2O or 50 ng/g DT was administered ip on days -2, -1, 1, 3, & 5. Colonic LPLs from each 
mouse were harvested on day 7. Cells were stimulated ex vivo, followed by ICS. Dot plots show 










Figure 10: Mitigation of IL-17 response to ETBF in the absence of Tregs is independent of 
IFN-γ. B6.Foxp3DTR and B6.Foxp3DTRxIFNγ-/- mice were inoculated with ETBF on day 0. Either 
150ul purified sterile H2O or 50 ng/g DT was administered ip on days -2, -1, 1, 3, & 5. Colonic 
LPLs from 1-2 mice per group were harvested on day 7. Cells were stimulated ex vivo, followed 







Figure 11: Reduced ETBF tumorigenesis in the absence of Tregs is independent of IFN-γ. 
B6.Foxp3DTR x IFNγ-/- x Min mice were inoculated with ETBF on day 0. Either 150 μl purified 
sterile H2O or 50 ng/g DT was administered ip on days -1, 0, 1, 3, and every other day until 
sacrifice and harvest. Colons were harvested on day 13, cleaned, rolled, and fixed in 10% 
formalin, paraffin embedded and H&E stained for microadenoma counting per colon. Each 
symbol represents 1 colon, and error bars represent 1 standard deviation from the mean in each 
direction. 2-5 mice per group per experiment. Combined data from 2 experiments. IFNγ+/+ x Min 







Figure 12: IL-17+ Foxp3+ Tregs infiltrate ETBF-infected colons. Min mice were inoculated 
with ETBF on day 0. At 10 weeks, colonic LPLs were harvested from colon tumors (left) and 
adjacent non-tumor colon tissue (right). Cells were stimulated ex vivo, followed by ICS. Dot 





Figure 13: Mixed chimeras reveal a cell extrinsic requirement for Foxp3 in Th17 
differentiation. A) Schematic of the experiment designed to determine whether Foxp3 
expression is a cell extrinsic or intrinsic requirement for Th17 differentiation. B) 107 total bone 
marrow cells from B6.Foxp3DTR CD45.2 mice only (DT control), or mixed 1:1 with bone marrow 
cells from B6.Foxp3WT CD45.1 mice, were transferred retro-orbitally into Rag1-/- recipients that 
had received 300 rads irradiation 5-6 hours prior. Following 6 weeks for hematopoietic cell 
reconstitution, mice were inoculated with ETBF or sham on day 0, and either 150 μl purified 
sterile H2O or 50 ng/g DT was administered ip on days -2, -1, 1, 3, & 5. Colonic LPLs from 1-2 
mice were harvested on day 7 following ETBF or Sham inoculation. Cells were stimulated ex 










Figure 14: Foxp3+ Tregs are not necessary to maintain an established Th17 response. Colon 
LPLs from 1 B6.Foxp3DTR mouse per group were harvested on day 7 following inoculation with 
ETBF or sham on day 0. For no depletion and early depletion, purified sterile H2O or DT, 
respectively, was administered ip on days -2, -1, 1, 3, & 5. For late depletion, DT was 
administered ip on days 1, 3, & 5. Cells were stimulated ex vivo, followed by ICS. Plots show 







Figure 15: Anti-IL-2 restores the Th17 response to ETBF in the absence of Foxp3+ Tregs. 4-
9 B6.Foxp3DTR mice per group were inoculated with ETBF. Either 150 μl purified sterile H2O 
or 50 ng/g DT was administered ip on days -2, -1, 1, 3, & 5, and either rat anti-mouse IL-2 
(S4B6-1) or rat IgG2a isotype (JES3-19F) was delivered ip daily (day -2 through day 6). Colonic 
LPLs from each mouse were harvested on day 7. Cells were stimulated ex vivo, followed by ICS. 
A) Representative dot plots show viable CD3+ CD4+ Foxp3- LPLs from 1 mouse per group. aIL-
2, anti-mouse IL-2. B) Aggregate data from Figure 15A showing percentage of viable CD3+ 
CD4+ Foxp3- LPLs that are IL-17A+. Each symbol represents one B6.Foxp3DTR mouse, and error 
bars represent 1 standard deviation from the mean in each direction. Isotype-treated animals were 








Figure 16: Anti-IL-2 restores the total tissue Il17a response to ETBF in the absence of 
Foxp3+ Tregs. Tissue for RNA isolation was taken from the middle colon from each mouse in 
Figure 15B and Taqman qRT-PCR was performed for IL-17A. ^Ct was calculated by subtracting 
Ct of Gapdh from Ct of IL-17A and averaging 2 technical replicates. Each symbol represents one 






Figure 17: Foxp3+ Tregs do not inhibit Il2 transcription by effector T cells. 6-12 
B6.Foxp3DTR mice per group were inoculated with ETBF on day 0. Either 150 μl purified sterile 
H2O or 50 ng/g DT was administered ip on days -2, -1, 1, 3, & 5. Colonic LPLs from 1-3 mice 
per group were harvested on day 7 for fluorescence-associated cell sorting. Effector T cells 
(CD11b-, Foxp3-, CD4+ or CD8+) were sorted from Treg-depleted mice (, +DT) and from 
Treg-sufficient mice (, No DT). RNA was isolated from Trizol and Taqman qRT-PCR was 
performed for indicated genes. Gapdh was used as housekeeping control for total RNA quantity 
(^Ct), and average of 2 technical replicates were used for each sample. CD4+ Foxp3+ Tregs were 
sorted from Treg-sufficient mice as the reference sample for calculating ^^Ct. Fold change = 2^-
(^^Ct). Each symbol represents one mouse (or pooled group), and error bars represent 1 standard 
deviation from the mean in each direction. Holm-Sidak method for multiple comparisons was 







Figure 18: Anti-IL-2 restores ETBF-induced microadenoma formation yet minimizes colitis 
in the absence of Foxp3+ Tregs. B6.Foxp3DTRxMin mice were inoculated with ETBF on day 0. 
Either 150 μl purified sterile H2O or 50 ng/g DT was administered ip on days -1, 0, 1, 3, and 
every other day until sacrifice and harvest. Either rat anti-mouse IL-2 (S4B6-1) or rat IgG2a 
isotype (JES3-19F) was delivered ip daily (day -1 through day 13). Colons were harvested on day 
13, cleaned, rolled, and fixed in 10% formalin for histology & scoring. A) Microadenomas were 
counted per colon and include 2 separate experiments with 3-12 mice per group per experiment. 
DT animals treated with isotype Ab (N=10) were not different from DT only-treated animals 
(N=18), so DT animals treated with or without isotype Ab were combined. Each symbol 
represents one mouse, and error bars represent 1 standard deviation from the mean in each 
direction. IFNγ-/- x Min + DT microadenoma counts from Figure 11 are also shown for easier 
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